Levodopa-induced dyskinesias.
Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG.
Mov Disord. 2007 Jul 30;22(10):1379-1389. doi: 10.1002/mds.21475.
Drug-induced dyskinesias.
Damier P.
Curr Opin Neurol. 2009 Aug;22(4):394-9. doi: 10.1097/WCO.0b013e32832d9dc4.
Optimising levodopa therapy.
Abbruzzese G.
Neurol Sci. 2008 Dec;29 Suppl 5:S377-9. doi: 10.1007/s10072-008-1051-x.
Malignant syndromes: current advances.
Tao M, Li J, Wang X, Tian X.
Expert Opin Drug Saf. 2021 Sep;20(9):1075-1085. doi: 10.1080/14740338.2021.1919622. Epub 2021 Apr 26.
L-DOPA for Parkinson's disease-a bittersweet pill.
Lane EL.
Eur J Neurosci. 2019 Feb;49(3):384-398. doi: 10.1111/ejn.14119. Epub 2018 Sep 16.
Levodopa: A new look at an old friend.
Olanow CW, Stocchi F.
Mov Disord. 2018 Jul;33(6):859-866. doi: 10.1002/mds.27216. Epub 2017 Nov 27.
Extended-Release Amantadine for Levodopa-Induced Dyskinesia.
Dashtipour K, Tafreshi AR, Pahwa R, Lyons KE.
Expert Rev Neurother. 2019 Apr;19(4):293-299. doi: 10.1080/14737175.2019.1592677. Epub 2019 Mar 20.
Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P; Bi-Park 1 investigators.
Lancet Neurol. 2016 Feb;15(2):154-165. doi: 10.1016/S1474-4422(15)00336-1. Epub 2015 Dec 23.
Dyskinesia in Parkinson's disease: a clinical complication and an open scientific question.
Carta M, Hirsch E.
J Neural Transm (Vienna). 2018 Aug;125(8):1107. doi: 10.1007/s00702-018-1907-z.
Delta Opioid Pharmacology in Parkinson's Disease.
Mabrouk OS.
Handb Exp Pharmacol. 2018;247:261-275. doi: 10.1007/164_2016_16.
